Literature DB >> 26907881

Global strategies are required to cure and eliminate HBV infection.

Peter Revill1, Barbara Testoni2, Stephen Locarnini1, Fabien Zoulim2.   

Abstract

Chronic HBV infection results in >1 million deaths per year from cirrhosis and liver cancer. No known cure for chronic HBV exists, due in part to the continued presence of transcriptionally active DNA in the nucleus that is not directly targeted by current antiviral therapies. A coordinated approach is urgently needed to advance an HBV cure worldwide, such as those established in the HIV field. We propose the establishment of an International Coalition to Eliminate Hepatitis B Virus (ICE-HBV) to facilitate the formation of international working groups on HBV virology, immunology, innovative tools and clinical trials: to promote awareness and education as well as to drive changes in government policy and ensure funds are channelled to HBV cure research and drug development. With the ICE-HBV in place, it should be possible to enable a HBV cure within the next decade.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26907881     DOI: 10.1038/nrgastro.2016.7

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


  105 in total

Review 1.  New perspectives in the therapy of chronic hepatitis B.

Authors:  Pietro Lampertico; Yun Fan Liaw
Journal:  Gut       Date:  2012-05       Impact factor: 23.059

Review 2.  Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy.

Authors:  Ching-Lung Lai; Man-Fung Yuen
Journal:  Hepatology       Date:  2013-01       Impact factor: 17.425

3.  Anti-HBV DNA vaccination does not prevent relapse after discontinuation of analogues in the treatment of chronic hepatitis B: a randomised trial--ANRS HB02 VAC-ADN.

Authors:  H Fontaine; S Kahi; C Chazallon; M Bourgine; A Varaut; C Buffet; O Godon; J F Meritet; Y Saïdi; M L Michel; D Scott-Algara; J P Aboulker; S Pol
Journal:  Gut       Date:  2014-02-20       Impact factor: 23.059

4.  Progress towards an HIV cure: update from the 2014 International AIDS Society Symposium.

Authors:  Jenny Louise Anderson; Rémi Fromentin; Giulio Maria Corbelli; Lars Østergaard; Anna Laura Ross
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

5.  Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.

Authors:  Christopher Koh; Laetitia Canini; Harel Dahari; Xiongce Zhao; Susan L Uprichard; Vanessa Haynes-Williams; Mark A Winters; Gitanjali Subramanya; Stewart L Cooper; Peter Pinto; Erin F Wolff; Rachel Bishop; Ma Ai Thanda Han; Scott J Cotler; David E Kleiner; Onur Keskin; Ramazan Idilman; Cihan Yurdaydin; Jeffrey S Glenn; Theo Heller
Journal:  Lancet Infect Dis       Date:  2015-07-16       Impact factor: 25.071

6.  A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.

Authors:  Manabu Kaneko; Koichi Watashi; Shinji Kamisuki; Hiroki Matsunaga; Masashi Iwamoto; Fumihiro Kawai; Hirofumi Ohashi; Senko Tsukuda; Satomi Shimura; Ryosuke Suzuki; Hideki Aizaki; Masaya Sugiyama; Sam-Yong Park; Takayoshi Ito; Naoko Ohtani; Fumio Sugawara; Yasuhito Tanaka; Masashi Mizokami; Camille Sureau; Takaji Wakita
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

7.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.

Authors:  Stephanos J Hadziyannis; Vassilios Sevastianos; Irene Rapti; Dimitrios Vassilopoulos; Emilia Hadziyannis
Journal:  Gastroenterology       Date:  2012-05-31       Impact factor: 22.682

8.  Early inhibition of hepatocyte innate responses by hepatitis B virus.

Authors:  Souphalone Luangsay; Marion Gruffaz; Nathalie Isorce; Barbara Testoni; Maud Michelet; Suzanne Faure-Dupuy; Sarah Maadadi; Malika Ait-Goughoulte; Romain Parent; Michel Rivoire; Hassan Javanbakht; Julie Lucifora; David Durantel; Fabien Zoulim
Journal:  J Hepatol       Date:  2015-07-26       Impact factor: 25.083

9.  Meta-analysis: Treatment of hepatitis B infection reduces risk of hepatocellular carcinoma.

Authors:  J J Y Sung; K K F Tsoi; V W S Wong; K C T Li; H L Y Chan
Journal:  Aliment Pharmacol Ther       Date:  2008-07-24       Impact factor: 8.171

10.  The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo.

Authors:  Su-Ru Lin; Hung-Chih Yang; Yi-Ting Kuo; Chun-Jen Liu; Ta-Yu Yang; Ku-Chun Sung; You-Yu Lin; Hurng-Yi Wang; Chih-Chiang Wang; Yueh-Chi Shen; Fang-Yi Wu; Jia-Horng Kao; Ding-Shinn Chen; Pei-Jer Chen
Journal:  Mol Ther Nucleic Acids       Date:  2014-08-19       Impact factor: 10.183

View more
  49 in total

1.  Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.

Authors:  Hironori Nishitsuji; Hiromi Yamamoto; Ritsuko Shiina; Keisuke Harada; Saneyuki Ujino; Kunitada Shimotohno
Journal:  J Vis Exp       Date:  2017-02-01       Impact factor: 1.355

2.  Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Authors:  Janine Kah; Sarene Koh; Tassilo Volz; Erica Ceccarello; Lena Allweiss; Marc Lütgehetmann; Antonio Bertoletti; Maura Dandri
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 3.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment.

Authors:  Kasha P Singh; Megan Crane; Jennifer Audsley; Anchalee Avihingsanon; Joe Sasadeusz; Sharon R Lewin
Journal:  AIDS       Date:  2017-09-24       Impact factor: 4.177

4.  Untypable genotype restriction patterns and surface gene variants of hepatitis B virus isolates.

Authors:  Michael O Baclig; Karen G Reyes; Veni R Liles; Juliet Gopez-Cervantes
Journal:  Int J Mol Epidemiol Genet       Date:  2017-06-20

5.  A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations.

Authors:  Qiao Wang; Eleftherios Michailidis; Yingpu Yu; Zijun Wang; Arlene M Hurley; Deena A Oren; Christian T Mayer; Anna Gazumyan; Zhenmi Liu; Yunjiao Zhou; Till Schoofs; Kai-Hui Yao; Jan P Nieke; Jianbo Wu; Qingling Jiang; Chenhui Zou; Mohanmmad Kabbani; Corrine Quirk; Thiago Oliveira; Kalsang Chhosphel; Qianqian Zhang; William M Schneider; Cyprien Jahan; Tianlei Ying; Jill Horowitz; Marina Caskey; Mila Jankovic; Davide F Robbiani; Yumei Wen; Ype P de Jong; Charles M Rice; Michel C Nussenzweig
Journal:  Cell Host Microbe       Date:  2020-06-05       Impact factor: 21.023

Review 6.  HBV replication inhibitors.

Authors:  Claire Pierra Rouviere; Cyril B Dousson; John E Tavis
Journal:  Antiviral Res       Date:  2020-05-05       Impact factor: 5.970

7.  Hepatitis B Virus Infection and Organ Transplantation.

Authors:  Walid S Ayoub; Paul Martin; Kalyan Ram Bhamidimarri
Journal:  Gastroenterol Hepatol (N Y)       Date:  2018-01

8.  Bufalin inhibits hepatitis B virus-associated hepatocellular carcinoma development through androgen receptor dephosphorylation and cell cycle-related kinase degradation.

Authors:  Zhuo Yu; Hai Feng; Yunhui Zhuo; Man Li; Xiaojun Zhu; Lingying Huang; Xin Zhang; Zhenhua Zhou; Chao Zheng; Yun Jiang; Fan Le; Dae-Yeul Yu; Alfred Szelok Cheng; Xuehua Sun; Yueqiu Gao
Journal:  Cell Oncol (Dordr)       Date:  2020-07-04       Impact factor: 6.730

Review 9.  The evolution and clinical impact of hepatitis B virus genome diversity.

Authors:  Peter A Revill; Thomas Tu; Hans J Netter; Lilly K W Yuen; Stephen A Locarnini; Margaret Littlejohn
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-05-28       Impact factor: 46.802

10.  Multiple Drug Transporters Are Involved in Renal Secretion of Entecavir.

Authors:  Xi Yang; Zhiyuan Ma; Sisi Zhou; Yayun Weng; Hongmei Lei; Su Zeng; Liping Li; Huidi Jiang
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.